SinuSys Launches Two Vent-Os System Devices
SinuSys’ is launching two versions of its Vent-Os system in the EU, following receipt of CE Mark certification, Palo Alto, Calif., devicemaker said Tuesday.
The devices are collectively indicated for the treatment of front and sphenoid sinusitis and maxillary disease, with the Vent-Os sinus dilation system demonstrating ability to maintain patent maxillary sinus ostia at 12 months in 93 percent of treated patients, the company claims.
The low-pressure systems are small, self-expanding and gradually opens the sinus ostia, unlike balloon dilation devices that rely on rapid, high-pressure inflation, the devicemaker adds.
According to the company, 8 percent of adults worldwide are affected with chronic sinusitis. Many of these patients are treated with oral antibiotics and/or nasal steroids, which can boost antibiotic resistance and lead to unwanted side effects.
In the U.S., the Vent-Os system is cleared for maxillary dilation, but not for frontal and sphenoid sinus treatment. — Jason Scott